BioSpace News Archive

Halberd Corporation spins off new subsidiary to take unconventional approach to cancer treatment.

AstraZeneca and Ionis reported that their NEURO-TTRansform Phase III trial in hereditary transthyretin-mediated amyloid polyneuropathy hit its co-primary endpoints.

Therorna brought in $42 million to advance its circular RNA platform, while Carbon Biosciences banked $38 million to develop therapies for genetic diseases, beginning with cystic fibrosis.

Acer Therapeutics and Relief Therapeutics announced the FDA has denied their NDA for ACER-001 (sodium phenylbutyrate) for the treatment of urea cycle disorders.

Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTA TM ) in adult patients that met primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview at the Alliance Global Partners Summer Healthcare Conference.

CannaLean Biotechs is happy to announce “first patient in,” under its phase 2a, randomized, double-blind, placebo-controlled, multicenter clinical trial, for lowering blood cholesterol levels in patients with hyperlipidemia (increased levels of lipids in the blood).

Ardelyx, Inc. (Nasdaq: ARDX), today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022.

Tranquis plans to start a Phase 2 trial in people living with ALS by the end of 2022.

Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (“FDA”) cleared the Company’s Investigational New Drug Application (“IND”) for NXP800, which includes the Phase 1 clinical trial protocol.